MedTrace Logo

EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries

NCT01078402 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 809

Last updated 2013-02-12

Study results available
· View outcomes & findings →

Summary

This is a non-interventional, post-marketing, observational study (PMOS) in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication. No data currently exists to characterize patient populations being prescribed Humira in Eastern Europe. Further, it is important to establish the clinical outcome and tolerability of Humira in Eastern European patients, as well as their compliance with Humira treatment, in particular the acceptability of self-injection, which may influence all of the above in routine clinical practice.

Conditions

  • Ankylosing Spondylitis (AS)
  • Psoriatic Arthritis (PsA
  • Rheumatoid Arthritis (RA

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Maja Hojnik · AbbVie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Croatia
  • Hungary
  • Israel
  • Poland
  • Romania
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078402 on ClinicalTrials.gov